AI assistant
ACHIEVE LIFE SCIENCES, INC. — Director's Dealing 2014
Aug 14, 2014
33882_dirs_2014-08-14_0a26d6cd-cb27-4b51-ab28-55ea9fd6b7c4.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: ONCOGENEX PHARMACEUTICALS, INC. (OGXI)
CIK: 0000949858
Period of Report: 2014-08-12
Reporting Person: Cormack Scott Daniel (Director, President and CEO)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2014-08-12 | Common Stock | M | 37500 | $0.00 | Acquired | 102480 | Direct |
| 2014-08-13 | Common Stock | S | 18341 | $3.17 | Disposed | 84139 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2014-08-12 | Restricted Stock Unit (RSU) | $ | M | 37500 | Disposed | 2014-09-11 | Common Stock (37500) | Direct |
Footnotes
F1: Represents shares of common stock acquired upon settlement of the restricted stock units ("RSUs") listed in Table II.
F2: Represents shares of common stock that have been sold by the issuer to satisfy the tax liability in connection with the settlement of RSUs.
F3: Each RSU represents a contingent right to receive one share of the issuer's common stock at settlement.
F4: Pursuant to the terms of the RSU, the total underlying shares vest when certain performance criteria relating to the issuer are met.
F5: The RSUs expire 30 days from the date they vest.